Insider Selling: DexCom, Inc. (NASDAQ:DXCM) EVP Sells 426 Shares of Stock

DexCom, Inc. (NASDAQ:DXCM) EVP Sadie Stern sold 426 shares of the stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $69.15, for a total value of $29,457.90. Following the completion of the sale, the executive vice president now owns 75,451 shares of the company’s stock, valued at approximately $5,217,436.65. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

DexCom Stock Performance

DXCM stock traded down $0.08 during trading on Wednesday, hitting $68.47. 3,960,676 shares of the company’s stock traded hands, compared to its average volume of 3,787,237. The stock has a market capitalization of $27.23 billion, a price-to-earnings ratio of 43.24, a price-to-earnings-growth ratio of 2.12 and a beta of 1.18. DexCom, Inc. has a 52 week low of $62.34 and a 52 week high of $142.00. The stock has a fifty day moving average price of $84.93 and a two-hundred day moving average price of $112.21. The company has a quick ratio of 2.48, a current ratio of 2.82 and a debt-to-equity ratio of 1.00.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings data on Thursday, July 25th. The medical device company reported $0.43 earnings per share for the quarter, beating analysts’ consensus estimates of $0.39 by $0.04. DexCom had a net margin of 16.95% and a return on equity of 31.41%. The business had revenue of $1 billion during the quarter, compared to the consensus estimate of $1.04 billion. During the same quarter in the prior year, the firm earned $0.34 EPS. The company’s revenue for the quarter was up 15.3% compared to the same quarter last year. As a group, equities analysts anticipate that DexCom, Inc. will post 1.69 EPS for the current fiscal year.

Analysts Set New Price Targets

Several brokerages have issued reports on DXCM. Redburn Atlantic assumed coverage on shares of DexCom in a research report on Thursday, May 30th. They issued a “neutral” rating and a $130.00 price objective for the company. Wells Fargo & Company lowered their price target on shares of DexCom from $145.00 to $80.00 and set an “overweight” rating for the company in a report on Friday, July 26th. StockNews.com lowered shares of DexCom from a “buy” rating to a “hold” rating in a report on Monday, June 10th. UBS Group decreased their price objective on shares of DexCom from $163.00 to $95.00 and set a “buy” rating for the company in a research report on Friday, July 26th. Finally, Royal Bank of Canada dropped their target price on DexCom from $165.00 to $145.00 and set an “outperform” rating on the stock in a research report on Friday, July 26th. Seven research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $112.25.

Institutional Trading of DexCom

Institutional investors and hedge funds have recently made changes to their positions in the stock. Migdal Insurance & Financial Holdings Ltd. bought a new position in DexCom during the 2nd quarter worth $25,000. Sachetta LLC lifted its stake in DexCom by 255.2% in the second quarter. Sachetta LLC now owns 238 shares of the medical device company’s stock valued at $27,000 after buying an additional 171 shares during the last quarter. DSM Capital Partners LLC acquired a new position in shares of DexCom during the fourth quarter valued at $28,000. Crewe Advisors LLC bought a new position in shares of DexCom during the first quarter worth about $29,000. Finally, Riverview Trust Co acquired a new stake in shares of DexCom in the 1st quarter worth about $32,000. 97.75% of the stock is currently owned by institutional investors and hedge funds.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.